期刊文献+

急性肾损伤并肺部感染患者的抗菌方案阶段性调整探析

Staged Adjustment Mode of Antimicrobial Regimen for Acute Kidney Injury Patients with Pulmonary Infection
下载PDF
导出
摘要 目的:对急性肾损伤并肺部感染患者临床抗菌方案进行评价和调整。方法:利用PK/PD理论优化抗菌治疗的综合评价参数的定量范围,以及根据CCr值(内生肌酐清除率)对用药方案进行调整。结果及结论:急性肾损伤初期处于肾衰阶段的患者,CCr大幅下降,全程使用PIP/TAZ(哌拉西林/他唑巴坦)4.5 g q8h的给药方案,其给药剂量或给药频次明显超量。对该类患者,建议初期采用PIP/TAZ 4.5 g q24h^q36h的给药方案,逐步过渡到4.5 g q8h。 Objective: To discuss and analyze the rationality of antimicrobial regimen for the acute kidney injury patients with pulmonary infection, and to provide a rational reference for the staged adjustment of antimicrobial regimen. Methods: The quantitative range of comprehensive evaluation parameters were optimized using the PK/PD theory for antimicrobial therapies, and the endogenous creatinine clearance rate(CCr) was also considered. Results and Conclusion: For the acute kidney injury patients with the renal function at the stage of renal failure incipiently, with poor CCr, the regimen of PIP/TAZ as 4.5 g q8 h is obviously higher than the optimal dosage or interval time based on the PK/PD theory.The dosage of PIP/TAZ is suggested to initiate from 4.5 g qd or q36 h, and gradually transit to 4.5 g q8 h.
作者 陈瑶 宋香清
出处 《药学与临床研究》 2015年第6期578-580,共3页 Pharmaceutical and Clinical Research
关键词 药动学-药效学理论 内生肌酐清除率 急性肾损伤 肺部感染 哌拉西林他唑巴坦 PK/PD theory Endogenous creatinine clearance rate Acute kidney injury Pulmonary infection Piperacillin tazobactam
  • 相关文献

二级参考文献18

  • 1Dagan R, Klugman KP, Craig WA, et al.Evidence to sup- port the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy [J].JAntimocrob Chemother, 2001,47 ( 2 ) : 129.
  • 2Cazzola M, Di Perna F, Boveri B, et al.Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute ex- acetbation of chronic bronchitis[J].J Chemother, 2000, 12 (3):216.
  • 3Craig WA.The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiot- ic therapy[J].Respir Med, 2001,95 (Suppl A ) : 12.
  • 4Frimodt-Moller N.How predictive is PK/PD for antibacte- rial agents?[J]. IntJAntimicrobAgents,2002,19(4) :333.
  • 5Craig WA.Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men [J].Clin lnfect Dis, 1998,26 ( 1 ) : 1.
  • 6Craig W.Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens[J]. Eur J Clin Mi- crobiol Infect Dis, 1993,12 ( Suppl 1 ) : $6.
  • 7Holly MM, Maryanne B, Dadong L, et al,Phamacodynam- ic assessment of gatifloxacin against Streptococcus pneu- moniae[J]. Antimicobial Agents Chemother, 2001,45 (7) : 2 092.
  • 8Janknegt R, Wijnands W J, Stobberingh EE.Antibiotic pdi- cies in dutch hospitals for the treatment of pneamonia [J]. JAntimicrob Chemother, 1994,34 (3) : 169.
  • 9汪复,张婴元.实用抗感染治疗学[M].1版.北京:人民卫生出版社,2005:155-158、202-203、282-283.
  • 10劳海燕,杨敏,林秋晓,万波,冯聚锦.透析用水和透析液中细菌内毒素考察[J].中国药房,2008,19(1):46-48. 被引量:6

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部